Temat: "Parkinson disease" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline.
Autorzy:: Hattori N; Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Kabata D; Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Asada S; Kyowa Kirin Co., Ltd., Tokyo, Japan.
Kanda T; Kyowa Kirin Co., Ltd., Tokyo, Japan.
Nomura T; Kyowa Kirin Co., Ltd., Tokyo, Japan.
Shintani A; Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Mori A; Kyowa Kirin Co., Ltd., Tokyo, Japan.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2023 Dec 22; Vol. 18 (12), pp. e0269969. Date of Electronic Publication: 2023 Dec 22 (Print Publication: 2023).
Typ publikacji:: Journal Article
MeSH Terms:: Levodopa*/pharmacology
Parkinson Disease*/drug therapy
Humans ; Antiparkinson Agents/therapeutic use ; Catechol O-Methyltransferase ; Catechol O-Methyltransferase Inhibitors/therapeutic use ; Monoamine Oxidase

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Aberrations in temporal dynamics of cognitive processing induced by Parkinson's disease and Levodopa.
Autorzy:: Kiani MM; Department of Electrical Engineering, Sharif University of Technology, Tehran, Iran.
Heidari Beni MH; Department of Electrical Engineering, Sharif University of Technology, Tehran, Iran.
Aghajan H; Department of Electrical Engineering, Sharif University of Technology, Tehran, Iran. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Nov 18; Vol. 13 (1), pp. 20195. Date of Electronic Publication: 2023 Nov 18.
Typ publikacji:: Journal Article
MeSH Terms:: Levodopa*/therapeutic use
Levodopa*/pharmacology
Parkinson Disease*
Humans ; Antiparkinson Agents/therapeutic use ; Antiparkinson Agents/pharmacology ; Brain ; Cognition

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease.
Autorzy:: Yang Y; Department of Neurology, Affiliated Hospital of Southwest Jiaotong University & Chengdu Third People's Hospital, Chengdu, Sichuan, 610000, China. .
Gao F; Southwest Jiaotong University, Chengdu, Sichuan, 610000, China.
Gao L; Department of Neurology, Affiliated Hospital of Southwest Jiaotong University & Chengdu Third People's Hospital, Chengdu, Sichuan, 610000, China.
Miao J; Department of Neurology, Affiliated Hospital of Southwest Jiaotong University & Chengdu Third People's Hospital, Chengdu, Sichuan, 610000, China.; Pokaż więcej
Źródło:: BMC neurology [BMC Neurol] 2023 Oct 06; Vol. 23 (1), pp. 360. Date of Electronic Publication: 2023 Oct 06.
Typ publikacji:: Journal Article
MeSH Terms:: Levodopa*/therapeutic use
Parkinson Disease*/drug therapy
Humans ; Aged ; Middle Aged ; Benserazide/therapeutic use ; Antiparkinson Agents/therapeutic use ; Insulin-Like Growth Factor I ; Homocysteine

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Model-based optimization of controlled release formulation of levodopa for Parkinson's disease.
Autorzy:: Arav Y; Department of Applied Mathematics, Israeli Institute for Biological Research, PO Box 19, 7410001, Ness-Ziona, Israel. .
Zohar A; Ness-Ziona, Israel.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Sep 22; Vol. 13 (1), pp. 15869. Date of Electronic Publication: 2023 Sep 22.
Typ publikacji:: Journal Article
MeSH Terms:: Levodopa*/therapeutic use
Parkinson Disease*/drug therapy
Humans ; Delayed-Action Preparations ; Maintenance ; Patient Compliance

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Autorzy:: Kuo TT; National Defense Medical Center, Taipei 11490, Taiwan.
Chen YH; National Defense Medical Center, Taipei 11490, Taiwan.; Department of Neurological Surgery, Tri-Service General Hospital, Taipei 11490, Taiwan.
Wang V; Ph.D. Program in Translational Medicine, National Defense Medical Center and Academia Sinica, Taipei 11490, Taiwan.
Huang EY; Department of Pharmacology, National Defense Medical Center, Taipei 11490, Taiwan.
Ma KH; Graduate Institute of Biology and Anatomy, National Defense Medical Center, Taipei, 11490, Taiwan.
Greig NH; Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program National Institute on Aging, National Institutes of Health (NIH), Baltimore, MD 21224, USA.
Jung J; Peptron, Inc., Yuseong-gu, Daejeon 34054, Republic of Korea.
Choi HI; Peptron, Inc., Yuseong-gu, Daejeon 34054, Republic of Korea.
Olson L; Department of Neuroscience, Karolinska Institute, 171 77 Stockholm, Sweden.
Hoffer BJ; Department of Neurosurgery, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Tseng KY; National Defense Medical Center, Taipei 11490, Taiwan.; Department of Neurological Surgery, Tri-Service General Hospital, Taipei 11490, Taiwan.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Feb 28; Vol. 24 (5). Date of Electronic Publication: 2023 Feb 28.
Typ publikacji:: Journal Article
MeSH Terms:: Antiparkinson Agents*/adverse effects
Antiparkinson Agents*/therapeutic use
Dyskinesia, Drug-Induced*/drug therapy
Glucagon-Like Peptide-1 Receptor*/agonists
Levodopa*/adverse effects
Levodopa*/therapeutic use
Parkinson Disease*/drug therapy
Animals ; Mice ; Delayed-Action Preparations/therapeutic use ; Disease Models, Animal ; Dopamine/adverse effects ; Dopamine/therapeutic use ; Oxidopamine

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: The Early Treatment Phase in Parkinson's Disease: Not a Honeymoon for All, Not a Honeymoon at All?
Autorzy:: Alonso-Canovas A; Movement Disorders Unit, Neurology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.; Faculty of Medicine, Universidad de Alcalá, Alcalá de Henares, Spain.
Voeten J; Rijkswaterstaat, Eindhoven, The Netherlands.
Gifford L; Parkinson's Africa, London, UK.
Thomas O; PD Avengers, Vancouver, BC, Canada.
Lees AJ; The National Hospital for Neurology and Neurosurgery, London, UK.
Bloem BR; Department of Neurology, Radboud University Medical Center, Donders Institute for Brain and Cognition, Center of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands.; Pokaż więcej
Źródło:: Journal of Parkinson's disease [J Parkinsons Dis] 2023; Vol. 13 (3), pp. 323-328.
Typ publikacji:: Journal Article
MeSH Terms:: Levodopa*/therapeutic use
Parkinson Disease*/complications
Parkinson Disease*/drug therapy
Parkinson Disease*/diagnosis
Humans ; Antiparkinson Agents/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Effects of Oral Levodopa on Balance in People with Idiopathic Parkinson's Disease.
Autorzy:: Leroy T; Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Baggen RJ; Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.
Lefeber N; Rehabilitation Research Group, Department of Physiotherapy, Human Physiology and Anatomy, Vrije Universiteit Brussel, Brussels, Belgium.
Herssens N; Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.; Space Medicine Team, European Astronaut Centre, European Space Agency, Cologne, Germany.
Santens P; Department of Neurology, Ghent University Hospital, Ghent, Belgium.; Research Group BrainComm, Ghent University, Ghent, Belgium.
De Letter M; Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.; Research Group BrainComm, Ghent University, Ghent, Belgium.
Maes L; Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.; Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium.
Bouche K; Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.; Department of Physical and Rehabilitation Medicine, Ghent University Hospital, Ghent, Belgium.
Van Bladel A; Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.; Department of Physical and Rehabilitation Medicine, Ghent University Hospital, Ghent, Belgium.; Pokaż więcej
Źródło:: Journal of Parkinson's disease [J Parkinsons Dis] 2023; Vol. 13 (1), pp. 3-23.
Typ publikacji:: Meta-Analysis; Systematic Review
MeSH Terms:: Levodopa*/pharmacology
Parkinson Disease*/complications
Parkinson Disease*/drug therapy
Humans ; Antiparkinson Agents/therapeutic use ; Antiparkinson Agents/pharmacology ; Postural Balance/physiology ; Cognition

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson's Disease Therapy.
Autorzy:: Sukhanov I; Valdman Institute of Pharmacology, Pavlov First St. Petersburg State Medical University, 197022 St. Petersburg, Russia.; Institute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia.
Dorotenko A; Valdman Institute of Pharmacology, Pavlov First St. Petersburg State Medical University, 197022 St. Petersburg, Russia.
Fesenko Z; Institute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia.
Savchenko A; Valdman Institute of Pharmacology, Pavlov First St. Petersburg State Medical University, 197022 St. Petersburg, Russia.
Efimova EV; Institute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia.
Mor MS; Institute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia.
Belozertseva IV; Valdman Institute of Pharmacology, Pavlov First St. Petersburg State Medical University, 197022 St. Petersburg, Russia.
Sotnikova TD; Institute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia.
Gainetdinov RR; Institute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia.; St. Petersburg University Hospital, St. Petersburg State University, 199034 St. Petersburg, Russia.; Pokaż więcej
Źródło:: Biomolecules [Biomolecules] 2022 Dec 21; Vol. 13 (1). Date of Electronic Publication: 2022 Dec 21.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Levodopa*/pharmacology
Levodopa*/therapeutic use
Parkinson Disease*/drug therapy
Parkinson Disease*/etiology
Animals ; Rats ; Carbidopa ; Catalepsy/complications ; Catalepsy/drug therapy ; Dopamine

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: High-dose versus low-dose inhaled levodopa (CVT-301) in patients with Parkinson disease for the treatment of OFF episodes: a meta-analysis of randomized controlled trials.
Autorzy:: Yan Z; Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Wang W; Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, China.; Department of Neurosurgery, The First People's Hospital of Taicang City, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, Jiangsu Province, China.
Tao X; Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Cheng W; Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Zuo G; Department of Neurosurgery, The First People's Hospital of Taicang City, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, Jiangsu Province, China.
Chen Z; Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, China. .
Wang Z; Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, China. .
Chen G; Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, China.; Pokaż więcej
Źródło:: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2022 Nov; Vol. 43 (11), pp. 6233-6241. Date of Electronic Publication: 2022 Jul 30.
Typ publikacji:: Journal Article; Meta-Analysis; Review; Systematic Review
MeSH Terms:: Levodopa*/therapeutic use
Parkinson Disease*/drug therapy
Humans ; Antiparkinson Agents ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.
Autorzy:: Kamińska K; Department of Neuro-Psychopharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna street 12, 31-343, Kraków, Poland.
Lenda T; Department of Neuro-Psychopharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna street 12, 31-343, Kraków, Poland.
Konieczny J; Department of Neuro-Psychopharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna street 12, 31-343, Kraków, Poland.
Lorenc-Koci E; Department of Neuro-Psychopharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna street 12, 31-343, Kraków, Poland. .; Pokaż więcej
Źródło:: Psychopharmacology [Psychopharmacology (Berl)] 2022 Nov; Vol. 239 (11), pp. 3633-3656. Date of Electronic Publication: 2022 Sep 30.
Typ publikacji:: Journal Article
MeSH Terms:: Levodopa*/pharmacology
Parkinson Disease*/drug therapy
Animals ; Rats ; Oxidopamine ; Antidepressive Agents, Tricyclic/pharmacology ; Desipramine/pharmacology ; Dopamine/metabolism ; Serotonin/metabolism ; Antipruritics/metabolism ; Antipruritics/pharmacology ; Platelet Aggregation Inhibitors/metabolism ; Platelet Aggregation Inhibitors/pharmacology ; Antiparkinson Agents/pharmacology ; Antiparkinson Agents/metabolism ; Corpus Striatum ; Norepinephrine/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
Autorzy:: Hatano T; Department of Neurology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, 113-8421, Tokyo, Japan. .
Kano O; Department of Neurology, Faculty of Medicine, Toho University, 6-11-1 Omorinishi, Ota-ku, Tokyo, 143-8541, Japan.
Sengoku R; Department of Neurology, Jikei University Daisan Hospital, 4-11-1 Izumihoncho, Komae, Tokyo, 201-0003, Japan.
Yoritaka A; Department of Neurology, Juntendo University Koshigaya Hospital, 560 Fukuroyama, Koshigaya-shi, Saitama, 343-0032, Japan.
Suzuki K; Department of Neurology, Dokkyo Medical University Hospital, 880 Oaza Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi, 321-0293, Japan.
Nishikawa N; Department of Neurology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, 113-8421, Tokyo, Japan.; Department of Neurology, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi-cho, Kodaira-shi, Tokyo, 187-8551, Japan.
Mukai Y; Department of Neurology, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi-cho, Kodaira-shi, Tokyo, 187-8551, Japan.
Nomura K; Department of Neurology, Saitama Medical Center, Kawagoe-shi, Saitama, 350-8550, Japan.
Yoshida N; Department of Neurology, Saitama Medical Center, Kawagoe-shi, Saitama, 350-8550, Japan.
Seki M; Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Matsukawa MK; Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo, 173-0015, Japan.
Terashi H; Department of Neurology, Tokyo Medical University Hospital, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Kimura K; Department of Neurology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama-shi, Kanagawa, 232-0024, Japan.
Tashiro J; Sapporo Parkinson MS Neurological Clinic, Dai 27 Big Sapporo-kita Sky Building 12F, 7-6 Kita-7 jo Nishi-5 chome, Kita-ku, Sapporo-shi, Hokkaido, 060-0807, Japan.
Hirano S; Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8670, Japan.
Murakami H; Department of Neurology, The Jikei University Hospital, 3-19-18 Nishishinbashi, Minato-ku, Tokyo, 105-8471, Japan.
Joki H; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Uchiyama T; Department of Neurology, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Naka-ku, Hamamatsu-shi, Shizuoka, 430-8558, Japan.
Shimura H; Department of Neurology, Juntendo Tokyo Koto Geriatric Medical Center, 3-3-20 Shinsuna, Koto-ku, Tokyo, 136-0075, Japan.
Ogaki K; Department of Neurology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu-shi, Chiba, 279-0021, Japan.
Fukae J; Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takano-dai, Nerima-ku, Tokyo, 177-8521, Japan.
Tsuboi Y; Department of Neurology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Johnan-ku, Fukuoka, 814-0180, Japan.
Takahashi K; Department of Neurology, Tokyo Metropolitan Neurological Hospital, Musashidai 2-6-1, Fuchu-shi, Tokyo, 183-0042, Japan.
Yamamoto T; Department of Neurology, Saitama Medical University Hospital, Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Yanagisawa N; Medical Technology Innovation Center, Juntendo University and Juntendo Clinical Research and Trial Center, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Nagayama H; Department of Neurology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.; Pokaż więcej
Źródło:: BMC neurology [BMC Neurol] 2022 Mar 03; Vol. 22 (1), pp. 71. Date of Electronic Publication: 2022 Mar 03.
Typ publikacji:: Clinical Trial Protocol; Journal Article
MeSH Terms:: Levodopa*/adverse effects
Parkinson Disease*/drug therapy
Adenosine A2 Receptor Antagonists/pharmacology ; Adenosine A2 Receptor Antagonists/therapeutic use ; Adult ; Aged ; Aged, 80 and over ; Antiparkinson Agents/therapeutic use ; Humans ; Middle Aged ; Multicenter Studies as Topic ; Purines/pharmacology ; Purines/therapeutic use ; Randomized Controlled Trials as Topic

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Interactions of a boron-containing levodopa derivative on D 2 dopamine receptor and its effects in a Parkinson disease model.
Autorzy:: Abad-García A; Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón, s/n. Col. Casco de Santo Tomás, Del. Miguel Hidalgo, 11340, Mexico City, Mexico.
Ocampo-Néstor AL; Departamento de Nefrología, Hospital General de México 'Dr. Eduardo Liceaga', Dr. Balmis 148, Alc. Cuauhtémoc, 06720, Mexico City, Mexico.
Das BC; Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, 11201-5497, USA.
Farfán-García ED; Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón, s/n. Col. Casco de Santo Tomás, Del. Miguel Hidalgo, 11340, Mexico City, Mexico.
Bello M; Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón, s/n. Col. Casco de Santo Tomás, Del. Miguel Hidalgo, 11340, Mexico City, Mexico.
Trujillo-Ferrara JG; Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón, s/n. Col. Casco de Santo Tomás, Del. Miguel Hidalgo, 11340, Mexico City, Mexico.
Soriano-Ursúa MA; Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón, s/n. Col. Casco de Santo Tomás, Del. Miguel Hidalgo, 11340, Mexico City, Mexico. .; Pokaż więcej
Źródło:: Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry [J Biol Inorg Chem] 2022 Feb; Vol. 27 (1), pp. 121-131. Date of Electronic Publication: 2021 Nov 22.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Levodopa*/pharmacology
Levodopa*/therapeutic use
Parkinson Disease*/drug therapy
Animals ; Boron ; Mice

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.
Autorzy:: Elabi OF; School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK.
Davies JS; Institute of Life Sciences, School of Medicine, Swansea University, Swansea SA2 8PP, UK.
Lane EL; School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2021 Nov 16; Vol. 22 (22). Date of Electronic Publication: 2021 Nov 16.
Typ publikacji:: Journal Article
MeSH Terms:: Dopaminergic Neurons/*transplantation
Exenatide/*pharmacology
Glucagon-Like Peptide-1 Receptor/*agonists
Levodopa/*pharmacology
Liraglutide/*pharmacology
Parkinson Disease, Secondary/*drug therapy
Animals ; Cell Movement/drug effects ; Corpus Striatum/drug effects ; Corpus Striatum/metabolism ; Corpus Striatum/pathology ; Dopaminergic Neurons/cytology ; Dopaminergic Neurons/metabolism ; Drug Interactions ; Embryo, Mammalian ; Female ; Gene Expression ; Glucagon-Like Peptide-1 Receptor/genetics ; Glucagon-Like Peptide-1 Receptor/metabolism ; Graft Survival/physiology ; Insulin Resistance ; Leukocytes/drug effects ; Leukocytes/pathology ; Motor Activity/drug effects ; Motor Activity/physiology ; Neuroprotective Agents/pharmacology ; Oxidopamine/administration & dosage ; Parkinson Disease, Secondary/chemically induced ; Parkinson Disease, Secondary/genetics ; Parkinson Disease, Secondary/pathology ; Rats ; Rats, Sprague-Dawley ; Rats, Wistar

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Can Dopamine Responsiveness Be Predicted in Parkinson's Disease Without an Acute Administration Test?
Autorzy:: Betrouni N; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.
Moreau C; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.; CHU Lille, Neurology and Movement Disorders Department, Reference Center for Parkinson's Disease, Lille, France; NS-Park French Network.
Rolland AS; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.
Carrière N; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.; CHU Lille, Neurology and Movement Disorders Department, Reference Center for Parkinson's Disease, Lille, France; NS-Park French Network.; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille, France; NS-Park French Network.
Viard R; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille, France; NS-Park French Network.
Lopes R; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille, France; NS-Park French Network.
Kuchcinski G; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.; CHU Lille, Neuroradioloy Department, Lille, France.
Eusebio A; Aix Marseille Universitë, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, UMR CNRS 7289, Institut de Neuroscience de La Timone, Marseille, France; NS-Park French Network.
Thobois S; Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Neurologie C, Bron, France.
Hainque E; Dëpartement de Neurologie, Hôpital Pitië-Salpêtrière, AP-HP, Paris, France; NS-Park French Network.
Hubsch C; Fondation Ophtalmologique A de Rothschild, Unitë James Parkinson, Paris, France; NS-Park French Network.
Rascol O; University of Toulouse 3, University Hospital of Toulouse, INSERM, Departments of Neuroscience and Clinical Pharmacology, Clinical Investigation Center CIC 1436, Toulouse Parkinson Expert Center, NS-NeuroToul Center of Excellence for Neurodegenerative Disorders (COEN), Toulouse, France; NS-Park French Network.
Brefel C; University of Toulouse 3, University Hospital of Toulouse, INSERM, Departments of Neuroscience and Clinical Pharmacology, Clinical Investigation Center CIC 1436, Toulouse Parkinson Expert Center, NS-NeuroToul Center of Excellence for Neurodegenerative Disorders (COEN), Toulouse, France; NS-Park French Network.
Drapier S; Service de Neurologie, CHU Pont Chaillou, 2 rue Henri le Guilloux, Rennes cedex, France; NS-Park French Network.
Giordana C; Universitë Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand, France; NS-Park French Network.
Durif F; Universitë Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand, France; NS-Park French Network.
Maltête D; Department of Neurology, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France; NS-Park French Network.
Guehl D; Service d'Explorations Fonctionnelles du Système Nerveux, Institut des Maladies Neurodëgënëratives Cliniques, CHU de Bordeaux, Bordeaux, France; NS-Park French Network.
Hopes L; Neurology Department, Nancy University Hospital, Nancy, France; NS-Park French Network.
Rouaud T; Clinique Neurologique, Hôpital Guillaume et Renë Laennec, Boulevard Jacques Monod, Nantes Cedex, France; NS-Park French Network.
Jarraya B; Movement Disorders Unit, Foch Hospital, Universitë Paris-Saclay (UVSQ), INSERM U992, NeuroSpin, CEA Paris-Saclay, Suresnes, France; NS-Park French Network.
Benatru I; Service de Neurologie, Centre Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, Poitiers, France; NS-Park French Network.
Tranchant C; Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Institut de Gënëtique et de Biologie Molëculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Universitë de Strasbourg, Illkirch, France; Fëdëration de Mëdecine Translationnelle de Strasbourg (FMTS), Universitë de Strasbourg, Strasbourg, France; NS-Park French Network.
Tir M; Department of Neurosurgery, Amiens University Hospital, Amiens, France; Medical Imaging Unit, Amiens University Hospital, Amiens, France; BioFlowImage Research Group, Jules Verne University of Picardie, Amiens, France; NS-Park French Network.
Chupin M; CATI, Institut du Cerveau et de le Moelle Epinière, ICM, INSERM U1127, CNRS UMR7225, Sorbonne Universitë, Paris, France.
Bardinet E; Institut du Cerveau et de le Moelle Epinière, ICM, INSERM U1127, CNRS UMR7225, Sorbonne Universitë, Paris, France.
Defebvre L; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.; CHU Lille, Neurology and Movement Disorders Department, Reference Center for Parkinson's Disease, Lille, France; NS-Park French Network.
Corvol JC; Dëpartement de Neurologie, Hôpital Pitië-Salpêtrière, AP-HP, Paris, France; NS-Park French Network.; Facultë de Mëdecine de Sorbonne Universitë, UMR S 1127, INSERM U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle Epinière, Paris, France; NS-Park French Network.
Devos D; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.; CHU Lille, Neurology and Movement Disorders Department, Reference Center for Parkinson's Disease, Lille, France; NS-Park French Network.; Pokaż więcej
Corporate Authors:: PREDISTIM Study Group
Źródło:: Journal of Parkinson's disease [J Parkinsons Dis] 2022; Vol. 12 (7), pp. 2179-2190.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Levodopa*/therapeutic use
Parkinson Disease*/diagnostic imaging
Parkinson Disease*/drug therapy
Antiparkinson Agents/therapeutic use ; Dopamine ; Humans ; Magnetic Resonance Imaging

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: PEG-J replacement for duodenal levodopa infusion in Parkinson's disease patients: a retrospective study.
Autorzy:: Simoni S; Movement Disorders Center Neurology Department, Perugia General Hospital University of Perugia, P.le Severi 1, 06132, Perugia, Italy.; Neurology Department, Perugia General Hospital University of Perugia, Perugia, Italy.
Nigro P; Movement Disorders Center Neurology Department, Perugia General Hospital University of Perugia, P.le Severi 1, 06132, Perugia, Italy.
Filidei M; Neurology Department, Perugia General Hospital University of Perugia, Perugia, Italy.
Cappelletti G; Neurology Department, Perugia General Hospital University of Perugia, Perugia, Italy.
Paolini Paoletti F; Neurology Department, Perugia General Hospital University of Perugia, Perugia, Italy.
Castellani D; Endoscopic Section of Gastroenterology and Hepatology, Perugia General Hospital and University of Perugia, Perugia, Italy.
Gaggiotti M; Endoscopic Section of Gastroenterology and Hepatology, Perugia General Hospital and University of Perugia, Perugia, Italy.
Parnetti L; Neurology Department, Perugia General Hospital University of Perugia, Perugia, Italy.
Tambasco N; Movement Disorders Center Neurology Department, Perugia General Hospital University of Perugia, P.le Severi 1, 06132, Perugia, Italy. .; Neurology Department, Perugia General Hospital University of Perugia, Perugia, Italy. .; Pokaż więcej
Źródło:: BMC neurology [BMC Neurol] 2022 Jan 13; Vol. 22 (1), pp. 25. Date of Electronic Publication: 2022 Jan 13.
Typ publikacji:: Journal Article
MeSH Terms:: Levodopa*/adverse effects
Parkinson Disease*/drug therapy
Aged ; Gastrostomy ; Humans ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel.
Autorzy:: Kovács N; University of Pécs, Medical School, Pécs, Hungary.
Bergmann L; AbbVie Inc., North Chicago, IL, USA.
Anca-Herschkovitsch M; Edith Wolfson Medical Center, Holon, Israel.
Cubo E; Neurology Department, Hospital Universitario Burgos, Burgos, Spain.
Davis TL; Vanderbilt University Medical Center, Nashville, TN, USA.
Iansek R; Kingston Centre, Monash Health, Melbourne, Australia.
Siddiqui MS; Wake Forest School of Medicine, Winston Salem, NC, USA.
Simu M; Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.
Standaert DG; University of Alabama at Birmingham, Birmingham, AL, USA.
Chaudhuri KR; Parkinson's Foundation International Centre of Excellence, King's College Hospital, London, UK.; King's College Institute of Psychiatry, Psychology & Neuroscience, London, UK.
Bourgeois P; Department of Neurology AZ Groeninge, Kortrijk, Belgium.
Gao T; AbbVie Inc., North Chicago, IL, USA.
Kukreja P; AbbVie Inc., North Chicago, IL, USA.
Pontieri FE; Sapienza University of Rome, Rome, Italy.; Fondazione Santa Lucia, IRCSS, Rome, Italy.
Aldred J; Selkirk Neurology, Spokane, Washington, USA.; Pokaż więcej
Źródło:: Journal of Parkinson's disease [J Parkinsons Dis] 2022; Vol. 12 (3), pp. 917-926.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Carbidopa*/therapeutic use
Levodopa*/therapeutic use
Parkinson Disease*/drug therapy
Activities of Daily Living ; Antiparkinson Agents/therapeutic use ; Drug Combinations ; Dyskinesias ; Gels ; Humans ; Prospective Studies ; Quality of Life

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson's Disease.
Autorzy:: Verschuur CVM; Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Suwijn SR; Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
de Haan RJ; Department of Epidemiology and Data Science, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Boel JA; Department of Epidemiology and Data Science, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Post B; Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.
Bloem BR; Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.
van Hilten JJ; Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
van Laar T; Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands.
Tissingh G; Department of Neurology, Zuyderland Medical Center, Heerlen, The Netherlands.
Munts A; Department of Neurology, Excellent Klinieken, Dordrecht, The Netherlands.
Dijkgraaf MGW; Department of Epidemiology and Data Science, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
de Bie RMA; Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.; Pokaż więcej
Źródło:: Journal of Parkinson's disease [J Parkinsons Dis] 2022; Vol. 12 (7), pp. 2171-2178.
Typ publikacji:: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Levodopa*
Parkinson Disease*/drug therapy
Antiparkinson Agents ; Carbidopa ; Cost-Benefit Analysis ; Humans

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring.
Autorzy:: Contin M; Dipartimento di Scienze Biomediche e NeuroMotorie, Università di Bologna, Bologna, Italia.
Lopane G; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia.
Belotti LMB; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia.
Galletti M; Dipartimento di Scienze Biomediche e NeuroMotorie, Università di Bologna, Bologna, Italia.
Cortelli P; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia.; Dipartimento di Scienze Biomediche e NeuroMotorie, Università di Bologna, Bologna, Italia.
Calandra-Buonaura G; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia.; Dipartimento di Scienze Biomediche e NeuroMotorie, Università di Bologna, Bologna, Italia.; Pokaż więcej
Źródło:: Journal of Parkinson's disease [J Parkinsons Dis] 2022; Vol. 12 (8), pp. 2519-2530.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Levodopa*/therapeutic use
Parkinson Disease*/drug therapy
Male ; Humans ; Female ; Aged ; Antiparkinson Agents/adverse effects ; Carbidopa ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Eight-year follow-up outcome of subthalamic deep brain stimulation for Parkinson's disease: Maintenance of therapeutic efficacy with a relatively low levodopa dosage and stimulation intensity.
Autorzy:: Jiang L; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Chen W; Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Guo Q; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Yang C; Department of Neurosurgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Gu J; Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.
Xian W; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Liu Y; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Zheng Y; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Ye J; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Xu S; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Hu Y; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Wu L; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Chen J; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Qian H; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Fu X; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Liu J; Department of Neurosurgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Chen L; Department of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.; Pokaż więcej
Źródło:: CNS neuroscience & therapeutics [CNS Neurosci Ther] 2021 Nov; Vol. 27 (11), pp. 1366-1373. Date of Electronic Publication: 2021 Aug 05.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Subthalamic Nucleus*
Antiparkinson Agents/*therapeutic use
Deep Brain Stimulation/*methods
Levodopa/*therapeutic use
Parkinson Disease/*therapy
Aged ; Antiparkinson Agents/administration & dosage ; China ; Cognition ; Deep Brain Stimulation/psychology ; Emotions ; Female ; Follow-Up Studies ; Humans ; Levodopa/administration & dosage ; Male ; Mental Status and Dementia Tests ; Middle Aged ; Parkinson Disease/psychology ; Quality of Life ; Sleep Quality ; Surveys and Questionnaires ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Levodopa Challenge Test Predicts STN-DBS Outcomes in Various Parkinson's Disease Motor Subtypes: A More Accurate Judgment.
Autorzy:: Zheng Z; Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.; The First Clinical Medical College of Nanchang University, Nanchang, Jiangxi, China.
Yin Z; Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zhang B; Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.; Department of Neurology, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Fan H; Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Liu D; Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Zhou Y; Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.; The First Clinical Medical College of Nanchang University, Nanchang, Jiangxi, China.
Duan J; Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Zhou D; Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Wu X; Department of Neurosurgery, Changhai Hospital of the Second Military Medical University of Chinese PLA, Shanghai, China.
Lu G; Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.; Pokaż więcej
Źródło:: Neural plasticity [Neural Plast] 2021 Oct 21; Vol. 2021, pp. 4762027. Date of Electronic Publication: 2021 Oct 21 (Print Publication: 2021).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Judgment*
Antiparkinson Agents/*administration & dosage
Deep Brain Stimulation/*standards
Levodopa/*administration & dosage
Parkinson Disease/*therapy
Subthalamic Nucleus/*physiology
Aged ; Cohort Studies ; Deep Brain Stimulation/methods ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Parkinson Disease/diagnosis ; Parkinson Disease/drug therapy ; Predictive Value of Tests ; Reproducibility of Results ; Retrospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Parkinson disease"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język